Castle BiosciencesCSTL +5.67%72 Pretax Margin % is -17.22% as of Mar. 2026. GuruFocus rates CSTL with a GF Score™ of 72/100 and a GF Value™ of $29.16 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Castle Biosciences ranks worse than 53.2% on this metric.
The historical rank and industry rank for Castle Biosciences's Pretax Margin % or its related term are showing as below:
CSTL'
s Pretax Margin % Range Over the Past 10 Years
Min: -89.86 Med: -26.1 Max: 10.31
Current: -5.19
CSTL's Pretax Margin % is ranked worse than 53.2% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.56
vs CSTL: -5.19
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Castle Biosciences Pretax Margin % Related Terms
Castle Biosciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSTL vs FLGT, MYGN, PRE: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Castle Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (CSTL) has a Pretax Margin % of -17.22% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Castle Biosciences and its competitors. According to the industry distribution chart, Castle Biosciences ranks #108 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 53.2%.
Is Castle Biosciences' Pretax Margin % too high?
Castle Biosciences' current Pretax Margin % is -17.22%. Based on the distribution chart, Castle Biosciences ranks #108 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Pretax Margin % compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #108 out of 203 companies for Pretax Margin %. This places Castle Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current Pretax Margin % is -17.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.16, compared to a current price of $24.21 — trading 17% below its estimated fair value. The current Pretax Margin % is -17.22%. Castle Biosciences' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Pretax Margin % is -17.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of $24.21 is trading 17% below its estimated GF Value™ of $29.16.
GuruFocus considers Castle Biosciences to be Modestly Undervalued.
Key valuation signals for CSTL:
Pretax Margin %: -17.22%
GF Value™: $29.16 vs. price of $24.21 (17% below fair value)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
72GF Score
Get the complete analysis for CSTL
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
